Login to Your Account



All eyes on retinopathy as Novo heads to FDA panel

By Randy Osborne
Staff Writer

Monday, October 16, 2017

Whether and to what extent the risk of diabetic retinopathy will figure into deliberations of Wednesday’s FDA panel on Novo Nordisk A/S’ semaglutide stood as one of the main questions as investors scanned briefing documents made public Monday.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription